What do systematic reviews say?

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 110 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 152 participants
  Low

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid) vs placebo

Interventions (ibuprofen, tolfenamic acid) showed no clear difference in reduction in painful menstruation compared with placebo (low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 1 [0.11, 8.95]
  1 study · 20 participants
  Low

Interventions (ibuprofen, tolfenamic acid) vs placebo

It is very uncertain whether interventions (ibuprofen, tolfenamic acid) changes menstruation "more painful than normal" compared with placebo (very low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 0.71 [0.44, 1.44]
  1 study · 310 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 94 participants
  Low
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Naldemedine vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naloxone vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naloxone vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naloxone vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naloxone vs placebo

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  GRADE not reported

Naloxone vs placebo

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Naloxone vs placebo

The review found no eligible studies for this question.

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Naldemedine vs placebo

Naldemedine probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 2 [1.59, 2.52]
  2 studies · 418 participants
  Moderate

Methylnaltrexone vs placebo

Methylnaltrexone may leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 2.97 [2.13, 4.13]
  2 studies · 287 participants
  Low

Methylnaltrexone vs placebo

Methylnaltrexone probably leads to higher laxation response: risk of spontaneous rescue‐free bowel… compared with placebo (moderate certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 8.15 [4.76, 13.95]
  2 studies · 305 participants
  Moderate

Methylnaltrexone vs placebo

Methylnaltrexone may leads to higher laxation response: patient assessment of change in bowel statusgat… compared with placebo (low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 2.32 [1.64, 3.27]
  2 studies · 287 participants
  Low

Methylnaltrexone vs placebo

Methylnaltrexone showed no clear difference in symptoms of opioid withdrawalhin the medium term compared with placebo (low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 133 participants
  Low